Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: A single institution experience
Academic Article
Overview
MeSH Major
Antineoplastic Agents
Carcinoma, Large Cell
Lung Neoplasms
Neuroendocrine Tumors
abstract
The LCNEC has a high response rate to platinum-based neoadjuvant chemotherapy. Resected advanced-stage patients receiving combination neoadjuvant and (or) adjuvant chemotherapy may have a survival advantage. These therapies should be considered in resectable patients with LCNEC.
